凝血病
医学
止血
凝血酶原复合物浓缩物
重症监护医学
氨甲环酸
伊达鲁珠单抗
维生素K拮抗剂
混凝试验
止血剂
重组因子VIIa
凝血因子
血栓弹性成像
凝结
麻醉
华法林
外科
达比加群
内科学
失血
心房颤动
作者
Oliver Grottke,Lars Heubner
标识
DOI:10.1097/aco.0000000000001464
摘要
PCC is a valuable option for managing coagulopathy in specific settings, especially VKA and DOAC reversal. Based on current evidence, we caution against the use of PCC as a versatile hemostatic agent suitable for indications involving multiple clotting factor deficiencies for uncontrolled coagulopathic bleeding in trauma or other clinical settings outside anticoagulation reversal. The risk vs. benefit profile should be carefully examined, similar to any other agent.
科研通智能强力驱动
Strongly Powered by AbleSci AI